Platinum and Taxane-Induced Neuropathy and Its Impact on Quality of Life: A Single Institution Study. | ||
| SECI Oncology Journal | ||
| Volume 13, Issue 4, October 2025, Pages 253-261 PDF (326.41 K) | ||
| DOI: 10.21608/secioj.2025.457677 | ||
| Abstract | ||
| Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and challenging complication of platinum and taxane agents and can have a significant impact on patients' quality of life (QoL). Objective: This study aims to detect the frequency and severity of CIPN in patients receiving Platinum and Taxane compounds and their effect on QoL. Methods: This prospective study enrolled 47 patients receiving neurotoxic chemotherapy (taxanes and platinum-based agents) at Assiut University Hospital's Clinical Oncology Department between March 2023 and July 2024, with a median 6-month follow-up. CIPN was detected, graded, and assessed clinically by using the NCI-CTCAE v5.0 criteria and electrophysiologically through nerve conduction studies conducted in collaboration with the Neurology Department. Health-related quality of life (HRQoL) was evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Results: In this study, altered sensory symptoms occurred in 80-86.7% of patients across all regimens. Neuropathy grading revealed grade II in 44% of patients, grade I in 29%, and grade III in 25%. Platinum-based regimens were significantly associated with grade II neuropathy (p<0.001), while platinum+taxane combinations showed the highest rate of grade III neuropathy (p=0.05). Nerve conduction studies demonstrated significant post-chemotherapy reductions in sensory nerve action potential (SNAP) and motor conduction velocities (MCV) (p<0.001). Higher CIPN grades correlated significantly with worse global health status (commonly with patients received platinum + taxane combinations), reduced physical function, and increased symptom burden on both QLQ-C30 and NCI-CTCAE V5 scales (p<0.014). Conclusion: CIPN is a frequent and devastating complication in patients receiving taxane and platinum-based chemotherapy, with significant clinical, neurophysiological, and QoL implications. Future research should focus on strategies to prevent and mitigate this debilitating side effect. Trial Registration: (IRB 042023200122). | ||
| Keywords | ||
| Chemotherapy-induced peripheral neuropathy (CIPN); Platinum compounds; Taxanes; Quality of life (QoL); Nerve conduction studies | ||
|
Statistics Article View: 46 PDF Download: 40 |
||
